Abstract:Ground breaking advances in medicine, driven in part by major technologic developments in molecular biology have led us to a new model for cancer care that has been termed personalized, or precision medicine. Precision medicine is a model for making medical decisions that employs an innovative clinical approach and advanced tumor testing methods that are tailored to understanding an individual patient's tumor biology and the molecular drivers of their disease. This medical model includes a combination of diagnostic testing and specific treatment options that can be offered to patients at presentation and in theory throughout the course of their disease as new mutations arise with the development of disease recurrence. Although the precision medicine model offers incredible potential to transform cancer care, these advances are only meaningful when they reach the correct patients. The evolving paradigm of precision medicine is changing the practice of pathology, and the pathology community needs to be mindful of these changes because every tissue specimen represents a patient's life, and those patients are depending on the pathology community to handle their tissue correctly. The diagnostic tests performed in the pathology laboratory for precision medicine are increasingly complex, and pathologists along with the entire laboratory and clinical communities need to take steps to ensure that the right diagnosis is given to the right patient to inform the right treatment options, at the right time, along every step of the continuum of care for cancer patients. While hormone receptors and human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification have been the mainstay for risk-stratification, and treatment decision making in breast cancer since the early 2000's, the seminal work on gene expression by Perou and colleagues in the early 2000's opened the door for molecular testing in the prognostic and predictive assessment of breast cancer. Molecular testing is now part of the standard of care in the precision medicine model for breast cancer care. In this article, the reader will gain a better understanding of how the lack of standardization of pre-analytic factors has the potential to negatively impact the quality of the tissue specimen for downstream biomarker and molecular testing, which ultimately can negatively affect patient care. The reader will also gain insight into the current climate surrounding molecular testing in breast cancer.

The hallmarks of tissue-agnostic therapies and strategies for early anticancer drug discovery

The evolving landscape of tissue‐agnostic therapies in precision oncology

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Novel precision therapy for tumor driven by biomarkers

Abstract Wrk1-01: Agnostic trials in the field of targeted therapies

Precision Medicine in Cytopathology

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Histology Agnostic Drug Development: An Updated Review

Advanced Molecular Solutions for Cancer Therapy—The Good, the Bad, and the Ugly of the Biomarker Paradigm

Shifting the paradigm in personalized cancer care through next-generation therapeutics and computational pathology

Tissue biomarkers of immune checkpoint inhibitor therapy

Tumor-Agnostic Therapy—The Final Step Forward in the Cure for Human Neoplasms?

Optimized biomarker evaluation and molecular testing in the era of breast cancer precision medicine

Illuminating New Pathways in Cancer Precision Medicine

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution

Tissue microarrays and quantitative tissue-based image analysis as a tool for oncology biomarker and diagnostic development

Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development

Clinical trial design in the era of precision medicine

Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review

Exploring treatment options in cancer: Tumor treatment strategies